Seventy-one percent of pediatric patients with acquired hypothalamic obesity improved by at least one weight category after a year on setmelanotide, a figure that lands with particular force because the condition has historically resisted the tools that work elsewhere in obesity medicine. That single number from Rhythm Pharmaceuticals’ cluster of presentations at ENDO 2026 captures the strategic position the company is now pressing hard to defend and extend: a platform built around MC4R pathway agonism, applied across multiple rare neuroendocrine conditions where standard interventions routinely fail.
The breadth of the data package matters more than any single readout. Rhythm presented across three distinct disease areas in a single conference: setmelanotide’s long-term durability in acquired HO at 2.5 years (18.9% mean BMI reduction, n=11), real-world weight and healthcare utilization data in 286 patients with Bardet-Biedl syndrome, and early results for its oral candidate bivamelagon in acquired HO. The BBS real-world cohort is commercially significant precisely because it is large by rare-disease standards: 62% of adults achieved at least 10% body weight loss at 12 months, and outpatient obesity-related visit rates dropped meaningfully after treatment initiation. For payers already covering the FDA-approved BBS indication Rhythm secured in June 2022, that healthcare utilization signal is a direct argument against formulary restriction.
The bivamelagon data add a different kind of optionality. An oral MC4R agonist achieving up to 16.6% mean BMI reduction at 52 weeks in acquired HO patients who stayed on the highest dose throughout suggests the administration barrier that comes with injectable setmelanotide is not a permanent ceiling on market reach. Prader-Willi syndrome, meanwhile, represents a market where VYKAT XR (diazoxide choline) received FDA approval for hyperphagia in March 2025, meaning Rhythm is entering a competitive dynamic in PWS rather than an open field. The six-month PWS setmelanotide data presented at ENDO will need to demonstrate differentiation on both hyperphagia control and tolerability to convert prescribers.
The commercial lever most worth watching is payer acceptance of the acquired HO indication, which received FDA approval only in March 2026. Coverage policy for that newest indication will determine how quickly the weight-category improvement statistics translate into revenue, and that negotiation is still in early innings.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
